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Nemaline myopathies (NMs) are a group of congenital muscle 
diseases caused by mutations in at least 10 genes and associated with 
a range of clinical symptoms. NM is defined on muscle biopsy by the 
presence of cytoplasmic rod-like structures (nemaline rods) composed 
of cytoskeletal material. Myofiber smallness is also found in many 
cases of NM and may represent a cause of weakness that can be 
counteracted by treatment. We have used i.p. injection of activin type 
IIB receptor (ActRIIB)–mFc (an inhibitor of myostatin signaling) to 
promote hypertrophy and increase strength in our prior murine work; 
we therefore tested whether ActRIIB-mFc could improve weakness in 
NM mice through myofiber hypertrophy. We report a study of ActRIIB-
mFc treatment in the Acta1 H40Y mouse model of NM. Treatment of 
Acta1 H40Y mice produced significant increases in body mass, muscle 
mass, quadriceps myofiber size, and survival, but other measurements 
of strength (forelimb grip strength, ex vivo measurements of 
contractile function) did not improve. Our studies also identified that 
the complications of urethral obstruction are associated with mortality 
in male hemizygote Acta1 H40Y mice. The incidence of urethral 
obstruction and histologic evidence of chronic obstruction 
(inflammation) were significantly lower in Acta1 H40Y mice that had 
been treated with ActRIIB-mFc. ActRIIB-mFc treatment produces a 
mild benefit to the disease phenotype in Acta1 H40Y mice. 
The nemaline myopathies (NMs) are a clinically and genetically 
heterogeneous group of diseases, with a wide range of clinical 
phenotypes1 associated with mutations in at least 10 genes (ACTA1, 
NEB, TPM3, TPM2, TNNT1, CFL2, KBTBD13, KLHL40, KLHL41, and 
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LMOD3).2,3,4,5 With the exception of KBTBD13, the proteins encoded by 
all these genes are structural components of (or are associated 
with) the sarcomeric thin filament, which is an essential component of 
muscle contraction.6,7 The unifying feature of all NM cases is the 
presence of characteristic nemaline rods on skeletal muscle biopsy, 
which are aggregates of α-actinin and other sarcomeric proteins.8 
Although nemaline rods are a critical diagnostic feature of NM, their 
abundance, size, and distribution do not correlate well with disease 
severity,2 and their direct contribution to the weakness seen in NM is 
questionable. Another nonspecific pathologic feature that is seen in 
many cases of NM is myofiber smallness (or hypotrophy9), which most 
often involves the type 1 myofiber population. This pattern of myofiber 
hypotrophy is similar to that seen in other congenital myopathies, 
particularly congenital fiber-type disproportion, which has genetic and 
phenotypic overlap with some subsets of NM.10,11 Myofiber hypotrophy 
represents a potentially reversible pathologic phenotype that has a 
known association with muscle strength and should thus be considered 
as a therapeutic target for all cases of NM. Currently, there is no 
effective treatment for NM. 
Because myofiber smallness or suboptimal numbers of 
sarcomeres may contribute to weakness in NM, we hypothesized that 
induction of myofiber hypertrophy would be of symptomatic benefit in 
murine models of NM. Myostatin binds to (and signals through) the 
activin type IIB receptor (ActRIIB) to activate the transforming growth 
factor-β pathway, which prevents progression through the cell cycle 
and down-regulates several key processes related to myofiber 
hypertrophy.12,13 Nonfunctional decoys of ActRIIB can be used to 
inhibit this negative regulator of myofiber size, leading to myofiber 
hypertrophy. In our prior work, we used ActRIIB-mFc, a soluble activin 
type IIB receptor, to produce myofiber hypertrophy in wild-type (WT) 
mice and in two murine models of X-linked myotubular myopathy 
(XLMTM).14,15 In both these studies, the functional effect of 
hypertrophy on XLMTM muscle was significantly limited by the 
abnormalities of excitation-contraction coupling (ECC) that are also 
encountered in this disease. Because physiologic studies performed in 
NM mouse models16,17,18,19,20 and myofibers from human patients with 
NM21,22,23 do not indicate problems with ECC in NM, we hypothesized 
that myostatin/ActRIIB inhibition would produce both hypertrophy and 
significant functional benefits in murine models of NM. 
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Although a variety of murine models are available for testing, 
the Acta1 H40Y mouse represented a good first model for the 
evaluation of myostatin inhibition due to its behavioral phenotype and 
use in prior treatment studies.18 Acta1 H40Y mice develop moderate 
weakness, pathologic features similar to those of NM, and mortality of 
approximately half of hemizygote males at 1 to 3 months of age.18 The 
pathologic phenotype and clinical course of Acta1 H40Y mice was 
improved by crossing them with transgenic mice that produced 
myofiber hypertrophy through the overexpression of insulin-like 
growth factor-1 or FHL1 (but not c-ski),18 suggesting a benefit from at 
least some forms of hypertrophy in these mice. In this study, Acta1 
H40Y mice and WT littermates were injected twice per week with 10 
mg/kg of ActRIIB-mFc, starting at 2 weeks of age and lasting until 
death or 16 weeks of age. Treatment of Acta1 H40Y mice produced 
myofiber hypertrophy and improved survival without measurable 
increases in limb strength. We also identified an unexpected cause of 
death in Acta1 H40Y mice (urinary outlet obstruction) that may 
represent a broader-reaching cause of mortality in muscle disease 
models. Our studies have found an important new phenotype of 
weakness that may affect survival in murine models of neuromuscular 
disease, while also revealing that ActRIIB inhibition has the potential 
to improve pathologic features and disease course in NM. 
Materials and Methods 
Live Animal Studies 
All studies were performed with approval from the Institutional 
Animal Care and Use Committee at The Medical College of Wisconsin 
and Marquette University. Genotyping of the Acta1 H40Y mice was 
performed as previously described.18 Male WT and Acta1 H40Y mice 
were given i.p. injections twice per week with ActRIIB-mFC (also 
termed RAP-031; Acceleron Pharma, Cambridge, MA) at a dose of 10 
mg/kg or an equivalent volume of Tris-buffered saline (the vehicle 
used with ActRIIB-mFc) as previously described14 from 14 days until 4 
months of life. Animals were euthanized at 4 months of life because of 
a plateau in observable therapeutic effects. Animals were weighed 
daily during the treatment period beginning at 2 weeks of age when 
the first injection was given. Once the animals were weaned at the age 
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of 3 weeks, forelimb grip strength was measured biweekly using a grip 
strength meter (Columbus Instruments, Columbus, OH) by placing the 
animal on a horizontal grid and allowing it to pull away from the 
experimenter using only its forelimbs. The maximum of three 
independent measurements, with a 1-minute recovery period between 
measurements, was used for subsequent statistical analysis. To 
evaluate antigravity hanging performance, animals were tested 
biweekly by placing the animal on a rigid mesh surface, inverting the 
surface at a height of approximately 40 cm above a cage that 
contained at least 3 cm of bedding material, and recording the amount 
of time necessary for the animal to fall back into the cage. Animals 
that did not fall within 60 seconds were lowered back into their cages. 
The maximum of three independent measurements, with a 1-minute 
recovery period between measurements, was used for subsequent 
statistical analysis. Beginning at 1 month of age, mice were placed in a 
circular chamber (49.5 cm) and allowed to freely explore the enclosure 
for 10 minutes once a month. The open field tests were videotaped 
and analyzed for the total distance traveled by ANY-maze software 
version 3.96 (Stoelting, Wood Dale, IL). Also beginning at 1 month of 
age, animals were placed on a treadmill moving at 4 to 6 m/min 
(Columbus Instruments) every other week and monitored for the 
number of falls onto shock bars that occurred during 10 minutes. 
Pathologic Evaluation and Tissue Collection 
Animals were euthanized with carbon dioxide followed 
by cervical dislocation. Animals were photographed after the removal 
of the skin from the torso and limbs. The quadriceps, gastrocnemius, 
triceps, soleus, extensor digitorum longus (EDL), and diaphragm 
muscles were removed, weighed, and frozen in liquid nitrogen–cooled 
isopentane. 
In Vitro Contractile Properties/Fatigability 
Muscle Preparation 
Mice were euthanized with carbon dioxide and the EDL and 
soleus muscles rapidly removed and placed into a dissecting chamber 
containing a room temperature (23°C) Ringer solution (124 nM NaCl, 4 
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nM KCl, 1 nM MgCl2, 1 nM KH2PO4, 25 nM NaHCO3, and 2 nM CaCl2 
gassed with 95% O2 to 5% CO2, pH 7.40). Muscles were prepared for 
study by tying a small loop onto the distal and proximal tendon at the 
fiber tendon junction with 4-0 silk thread.24 To determine the 
contractile properties and fatigability of the EDL and soleus, each 
muscle was transferred to an experimental chamber containing Ringer 
solution (95% O2 to 5% CO2) and suspended with the 4-0 loops 
between a Cambridge model 352 ergometer (Aurora Scientific, Aurora, 
ON) and a fixed post. 
Isometric Force Measurement 
Each preparation was adjusted to its optimal length at which 
maximal twitch and tetanic tension was elicited (resting tension = 2 g) 
and isometric contractile properties studied as described previously 
and briefly reviewed here.25 The muscles were stimulated along their 
entire length with platinum wire electrodes. Peak twitch tension was 
elicited with 0.5-ms supermaximal pulse, and contraction time was 
measured as the time from the onset of force development to peak 
force. Half relaxation time (½RT) was the time required for force to 
decay to half of the maximum twitch value. Peak tetanic tension (Po) 
was elicited by stimulation at 100 Hz for 500 ms for the soleus and 
150 Hz for 200 ms for the EDL. For the twitch and tetanus, the 
maximum rate of force development and decay were determined by 
measuring the peak slope of the contraction and relaxation, 
respectively. The output from the transducer was amplified and 
sampled at 3.3 kHz by a Pentium computer using custom-made 
software. 
Force-Velocity and Power Curves 
The force-velocity association was determined, as described 
previously.25 At the plateau of peak tetanic contraction, the computer 
switched the ergometer from length to force control, and the load on 
the muscle was rapidly stepped to maintain three loads less than peak 
force. Force was held at each load for 100 ms for the soleus and 40 ms 
for the EDL, during which time the change in muscle length was 
monitored. The computer calculated the velocity of shortening from 
the slope of the length change during the last half of each load step. 
This procedure was repeated four times, such that 12 different loads 
NOT THE PUBLISHED VERSION; this is the author’s final, peer-reviewed manuscript. The published version may be 
accessed by following the link in the citation at the bottom of the page. 
American Journal of Pathology, Vol 186, No. 6 (June 2016): pg. 1568-1581. DOI. This article is © Elsevier and permission 
has been granted for this version to appear in e-Publications@Marquette. Elsevier does not grant permission for this 
article to be further copied/distributed or hosted elsewhere without the express permission from Elsevier. 
8 
 
were studied for each muscle. Loads were expressed as a percentage 
of peak force. Vmax was calculated by the straight-line form of the Hill 
equation (P0 − P)/V = P/b + a/b by using loads ≤50% of P0, where P is 
force, V is velocity, and a and b are constants with the dimensions of 
force and velocity, respectively. A hyperbolic curve was fit to the data 
by using the Hill equation (P + a) (V + b) = (P0 + a) b. 
Muscle power was calculated from the fitted force-velocity 
parameters and the maximum isometric force that was developed 
during the experiment.25 Absolute power was defined as the product of 
force (in mN) and shortening velocity (ML/s), yielding a final value of 
mN·ML−1·s−1. 
Muscle Histologic Findings 
Cross sections (8 μm) of isopentane-frozen quadriceps muscles 
were taken midway down the length of the muscle and stained with 
hematoxylin and eosin or Gomori trichrome for evaluation using an 
Olympus BX53 microscope with an Olympus DP72 camera and cellSens 
standard software (Olympus, Center Valley, PA). Fiber size was 
determined through measurements of MinFeret diameter14 because 
this measurement offers a myofiber size measurement that is 
relatively independent of fiber orientation.26 To evaluate fiber size and 
fiber type–specific responses, 8-μm frozen transverse sections of 
quadriceps muscle were double-stained with rabbit anti-dystrophin 
antibodies (ab15277; 1:100; Abcam, Cambridge, MA) and mouse 
monoclonal antibodies against myosin heavy chain type 2b (clone BF-
F3; 1:50; Developmental Studies Hybridoma Bank, Iowa City, IA). 
Secondary antibodies included Alexa Fluor 488–conjugated anti-mouse 
IgM (1:400; Sigma-Aldrich, St. Louis, MO) and Alexa Fluor 488–
conjugated anti-rabbit IgG (1:200; Molecular Probes, Carlsbad, CA). 
Because of variation in the number and type of oxidative fibers (type 1 
and 2a fibers) in mouse muscle, quantitation was performed by 
evaluating the type 2b myosin positive (glycolytic) and type 2b myosin 
negative (oxidative) populations on a whole slide scan of one 
quadriceps muscle from six vehicle-treated WT mice, six ActRIIB-mFc–
treated WT mice, six vehicle-treated Acta1 H40Y mice, and six 
ActRIIB-mFc–treated Acta1 H40Y mice. MinFeret diameter was 
evaluated using a novel automated technique developed by Dr. Lin 
Yang, as we have previously reported.14,15 Glutaraldehyde-fixed strips 
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of quadriceps muscle were collected from some mice, and electron 
microscopy was performed at the Medical College of Wisconsin's 
Electron Microscopy Core Facility. 
Organ Histologic Findings 
Organs were removed and fixed in 10% neutral buffered 
formalin for subsequent paraffin embedding at the Children's Hospital 
of Wisconsin Research Institute Histology Core, as previously 
described.27,28 The histopathologic findings of all thoracic and 
abdominal organs were assessed in a pilot group of four to six animals 
per treatment group using hematoxylin and eosin–stained slides. After 
recognizing the distribution of genitourinary disease in Acta1 H40Y 
males, the pelvic contents of subsequent cohorts of mice were 
dissected and histologically evaluated in the sagittal and axial planes. 
Because the axial view of the membranous urethra offered the most 
consistent view of skeletal muscle features between animals, blocks 
revealing axial sections of the membranous urethra at a comparable 
site (including the urethra, prostate, striated muscle, and rectum) 
were further evaluated by staining for dystrophin (ab15277; Abcam) 
or skeletal muscle actin (ab52218; Abcam) to determine the degree of 
NM-associated disease in urethral striated muscles and visualized 
using biotinylated horse anti-rabbit IgG (BA-1100; Vector 
Laboratories, Burlingame, CA). These findings were quantified by 
manually counting the number of fibers with actin-positive aggregates 
and the total number of fibers in a single medium-powered 
(magnification, ×100) field from each of the two urethral striated 
muscle fascicles that were reproducibly found along the lateral aspects 
of the urethra in axial sections. The skeletal muscle actin antibody that 
was used had cross-reactivity with cardiac actin and smooth muscle 
actin on testing of this antibody in cardiac and aortic tissue, 
respectively. 
Hypertrophic Pathway Studies 
Muscle tissues from the quadriceps muscle was frozen at 
the time of necropsy and stored at −80°C until analysis. Frozen 
muscles were crushed in liquid nitrogen and homogenized with lysing 
buffer (Cell Signaling Technology, Danvers, MA) containing protease 
inhibitor (Roche, Basel, Switzerland) and phosphatase inhibitor 
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(Roche). Western blot procedures were performed as previously 
described.15,29 Transferred proteins were probed with antibodies 
against a variety of antigens. Antibodies recognizing the following 
antigens were all obtained from Cell Signaling Technologies (Danvers, 
MA): Akt (4691), phospho-Akt (Ser473; 4060), phospho-Akt (Thr308; 
2965), p70-S6K (2708), phospho-p70-S6K (Thr421/Ser424; 9204), S6 
Ribosomal Protein (2217), phospho-S6 Ribosomal Protein 
(Ser240/244; 5364), phospho-eEF2k (Ser366; 3691), and phospho-
4E-BP1 (Thr37/46; 2855). Other antibodies used for Western blot 
studies recognize: myostatin (MAB788; R&D Systems, Minneapolis, 
MN), ActRIIB (ab76940; Abcam), and glyceraldehyde-3-phosphate 
dehydrogenase (G8795; Sigma-Aldrich) and were visualized using 
chemiluminescent horseradish peroxidase antibody detection reagent 
(Denville Scientific, Metuchen, NJ). Adequacy of transfer 
was determined by Ponceau S staining. Quantification of protein levels 
normalized to glyceraldehyde-3-phosphate dehydrogenase was 
performed with ImageJ software version 1.48 (NIH, Bethesda, MD; 
http://imagej.nih.gov/ij).30 Samples from four animals per treatment 
group were used for analysis. 
Statistical Analysis 
Statistical evaluation was performed using Prism software 
version 6.0 (GraphPad Software, Inc., La Jolla, CA) by SAS software 
version 9.2 (SAS Institute Inc., Cary, NC) or STATA software version 
13.1 (StataCorp, Chicago, IL). For statistical analysis of animal weight, 
forelimb grip strength, open field antigravity hanging performance, 
and treadmill performance, analyses of variance were performed with 
Bonferroni posttests. For muscle weight and mean myofiber diameter 
measurements, generalized linear models with Bonferroni posttests 
were performed. The survival analysis used Kaplan-Meier with a log-
rank test. The in vitro contractile property data were analyzed with 
multiple unpaired t-tests using Holm-Sidak method and α = 5%. For 
statistical analysis of Western blot data, t-tests were used to compare 
protein expression among different genotypes or treatments. 
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We assessed the effects of ActRIIB-mFc treatment in male 
heterozygote Acta1 H40Y mice starting at 14 days of life. Male mice 
were used because they reportedly experienced mortality (52% to 
61%) as a component of the disease phenotype, whereas mortality 
was only reported rarely in female mice (3% to 5%).18 Mice were 
dosed twice per week, consistent with our prior studies using ActRIIB-
mFc, and treatment efficacy was assessed using a variety of 
behavioral, physiologic, and pathologic measurements. Study time 
points included terminal stage of disease [in animals who reached this 
stage before 16 weeks of life (WOL)] or at 16 WOL. 
Weight Studies 
In animals that received vehicle injections, Acta1 H40Y mice 
were distinguishable from WT mice on the basis of weight beginning at 
5 WOL (P < 0.05) (Figure 1A). These differences increased and 
persisted during the period analyzed (up to 16 weeks of age) 
(P < 0.0001). ActRIIB-mFc–treated WT mice had significant weight 
gains compared with vehicle-treated WT mice starting at 5 WOL 
(P < 0.05), and this difference increased and persisted up to 16 weeks 
of age (P < 0.0001). ActRIIB-mFc treatment of Acta1 H40Y mice 
resulted in significant animal weight differences compared with 
vehicle-treated mutant mice starting at 6 WOL (P < 0.05), but the 
relative effect diminished over time as weight differences between 
these groups became nonsignificant at 9.5 WOL and persisted as a 
nonsignificant trend until the end of the study at 16 WOL. 
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Figure 1. Phenotypic findings in VEH- and ActRIIB-mFc–treated mice. A: Total body 
weight of VEH- and ActRIIB-mFc –treated mice. B: Forelimb grip force of VEH- and 
ActRIIB-mFc–treated mice. C: Open field activity (expressed in meters traveled in 10 
minutes) of VEH- and ActRIIB-mFc–treated mice. D: Kaplan-Meier survival curves for 
VEH- and ActRIIB-mFc–treated mice. Bars and asterisks denote significant 
differences between treatment groups with relevant comparisons. Note that the bar 
and asterisk in A illustrate a significant difference between the H40Y/VEH and 
H40Y/ActRIIB groups only between 6.5 and 9 weeks of age. The survival comparison 
in D between WT/ActRIIB and H40Y/ActRIIB did not reach statistical significance 
(P = 0.062). Data are expressed as means ± SEM (A–C). n = 25 for the 
WT/VEH group, 19 for the WT/ActRIIB group, 32 for the H40Y/VEH group, and 24 for 
the H40Y/ActRIIB group (A–C) and n = 28 for the WT/VEH group, 25 for the 
WT/ActRIIB group, 37 for the H40Y/VEH group, and 29 for the H40Y/ActRIIB group 
(D). ∗P < 0.05, ∗∗P < 0.01, and ∗∗∗P < 0.001. ActRIIB, ActRIIB-mFc treated; VEH, 
vehicle; WT, wild type. 
Behavioral Studies 
Muscle weakness was assessed by evaluating forelimb 
grip strength, antigravity hanging performance, open field activity, and 
treadmill performance. Interestingly, assays for open field activity and 
treadmill performance did not detect significant differences between 
vehicle-treated WT and Acta1 H40Y mice at 2 to 16 weeks of age, 
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despite the fact that a considerable number of Acta1 H40Y mice were 
dying during this period (Figure 1). Compared with WT animals, 
antigravity hanging ability was mildly impaired in Acta1 H40Y mice at 
4 to 6.5 WOL (WT/vehicle = 52.75 ± 3.96 seconds versus 
H40Y/vehicle = 27.85 ± 4.54 seconds at 4 WOL, P < 0.05) but was 
similar to the antigravity hanging performance of WT mice after 6.5 
WOL (WT/vehicle = 59.34 ± 0.66 seconds versus H40Y/vehicle 
= 51.51 ± 3.66 seconds at 7 WOL). Similarly, treatment of WT and 
Acta1 H40Y mice with ActRIIB-mFc did not produce significant changes 
in antigravity hanging performance (data not shown), open field 
activity (Figure 1C), and treadmill performance (data not shown) at 
any time point. There was, however, a clear distinction between the 
vehicle-treated WT and Acta1 H40Y mice using forelimb grip strength 
testing beginning at 3 WOL and persisting through the end of the 
study at 16 WOL (P < 0.0001) (Figure 1B). Treatment of WT mice with 
ActRIIB-mFc produced a persistent increase in grip strength starting at 
6 WOF (P < 0.01), which is similar in timing and extent to the effects 
of ActRIIB-mFc on WT mice in our prior studies.14,15 However, 
treatment of Acta1 H40Y mice with ActRIIB-mFc did not significantly 
increase forelimb grip strength, although there was a nonsignificant 
trend toward slightly increased forelimb grip strength in ActRIIB-mFc–
treated Acta1 H40Y mice. 
Survival 
Similar to the first published characterization of Acta1 H40Y 
mice, we found that vehicle-treated male Acta1 H40Y mice 
experienced significant mortality starting at approximately 6 WOL, 
with only 30% of vehicle-injected male Acta1 H40Y mice surviving to 
the end of the study at 16 WOL (Figure 1D). Interestingly, this 
mortality was not accompanied by a decline in behavioral test 
performance in most of the mice, which suggested that the cause of 
death was not related directly to the inability to move, eat, or breathe. 
As previously described,18,31 this mortality was not observed in female 
Acta1 H40Y mice, and our study focused on male Acta1 H40Y mice 
because survival was a desirable functional end point in a treatment 
study. Treatment of male Acta1 H40Y mice with ActRIIB-mFc produced 
a significant improvement in survival, including higher overall survival 
(55% survival to 16 WOL, P < 0.02). In addition, although none of the 
vehicle-treated WT mice died during the study, several ActRIIB-mFc–
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treated WT mice died at late stages of the trial because of apparent 
volume overload (indicated by large collections of nonbloody fluid in 
the thoracic cavity or both the thoracic and abdominal cavities). 
Histologic evaluation of tissue from the lungs of these animals did not 
reveal abnormalities. Specific gravity of the abdominal cavity fluid 
indicated that it was transudative rather than exudative (data not 
shown). This tended to occur in animals that were exceptionally large 
and heavy (>35 g) and that were thus receiving large volumes of fluid 
with each dose of ActRIIB-mFc. 
In Vitro Contractile Properties 
Treatment of WT mice with ActRIIB-mFc caused a significant 
increase in muscle weight and twitch force in both the soleus and EDL 
compared with vehicle-treated WT mice (Table 1). Peak muscle power 
was also significantly increased with treatment of WT in both the 
soleus (45.6 ± 9.3 versus 23.7 ± 4.1 mN·ML−1·s−1) and EDL 
(137.1 ± 32.9 versus 67.8 ± 23.0 mN·ML−1·s−1). The EDL of vehicle-
injected Acta1 H40Y mice had a depressed peak tetanic tension, and 
this effect was not reversed in the ActRIIB-mFc–treated Acta1 H40Y 
mice. The isometric ½RT was significantly prolonged in the soleus of 
vehicle-injected Acta1 H40Y mice but not the EDL (P < 0.05). In 
addition, the twitch contraction time revealed a trend toward 
prolongation (P < 0.1) in the soleus, but statistical evaluation was 
limited by the low numbers of vehicle-treated Acta1 H40Y mice 
available for this portion of the study (because most mice in this group 
died before this 16 WOL evaluation point). ActRIIB-mFc treatment of 
the Acta1 H40Y mice partially alleviated the lengthened soleus twitch 
duration by preventing prolongation of the ½RT (Table 1). These 
slightly differential abnormalities and treatment responses in the EDL 
and soleus muscles (which are enriched in glycolytic and oxidative 
fibers, respectively) suggest that the capacity for pharmacologically 
induced hypertrophy to improve weakness in NM may be partially 
dependent on fiber type. 
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Table 1. Contractile Properties of the Soleus and EDL in Treated and 
Untreated Mice 
Property WT/VEH (n = 
4) 
WT/ActRIIB-
mFc (n = 6) 
H40Y/VEH (n = 
2) 
H40Y/ActRIIB-mFc 
(n = 5) 
Soleus muscle 
 Weight (mg) 9.7 ± 1.0 12.9 ± 0.7∗ 9.4 ± 0.2 9.5 ± 1.3 
 Twitch data 
 Force (mN) 31 ± 4 45 ± 4∗ 34 ± 2 29 ± 5 
 Force 
(mN/CSA) 
35 ± 2 42 ± 4 38 ± 1 34 ± 6 
 CT (ms) 88 ± 8 79 ± 12 118 ± 10 130 ± 10† 
 ½RT (ms) 79 ± 8 79 ± 12 138 ± 9‡ 83 ± 22 
 Tetanus data 
 Force (mN) 162 ± 15 195 ± 19 139 ± 35 141 ± 20 
 Force 
(mN/CSA) 
187 ± 11 180 ± 18 155 ± 35 181 ± 52 
 +dP/dt 
(mN/s/CSA) 
1311 ± 53 1930 ± 150 1279 ± 122 1184 ± 327 
 −dP/dt 
(mN/s/CSA) 
−1124 ± 190 −946 ± 192 −537 ± 208 −804 ± 277 
 Vmax (mL/s) 0.94 ± 0.11 1.50 ± 0.35 
 
0.70 ± 0.01 
EDL muscle N = 5 N = 6 N = 2 N = 5 
 Weight (mg) 11.1 ± 1.3 18.3 ± 2.2∗ 8.9 ± 1.7 12.3 ± 1.0 
 Twitch data 
 Force (mN) 82 ± 7 117 ± 11∗ 61 ± 9 59 ± 8† 
 Force 
(mN/CSA) 
89 ± 8 83 ± 11 69 ± 3 60 ± 8 
 CT (ms) 41 ± 2 37 ± 1 45 ± 1 37 ± 1 
 ½RT (ms) 31 ± 3 26 ± 4 25 ± 2 36 ± 4 
 Tetanus data 
 Force (mN) 275 ± 36 339 ± 36 199 ± 1 170 ± 28† 
 Force 
(mN/CSA) 
300 ± 44 239 ± 28 232 ± 46 174 ± 27 
 +dP/dt 
(mN/s/CSA) 
4896 ± 521 4999 ± 576 4607 ± 33 3852 ± 568 
 −dP/dt 
(mN/s/CSA) 
−9977 ± 1659 −7065 ± 1160 −5943 ± 1244 −3674 ± 840 
 Vmax (ML/s) 1.87 ± 0.16 2.32 ± 0.25 
 
1.40 ± 0.20† 
Values are expressed as means ± SEM. 
CSA, cross sectional area; CT, contraction time; +dP/dt, maximum rate of force 
development; −dP/dt, maximum rate of force decay; EDL, extensor digitorum longus; 
½RT, half relaxation time; VEH, vehicle; WT, wild type. 
∗P < 0.05 between WT/ActRIIB-mFc and WT/VEH. 
†P < 0.05 between Acta1 H40Y/ActRIIB-mFc and WT/ActRIIB-mFc. 
‡P < 0.05 between Acta1 H40Y/VEH and WT/VEH. 
  
NOT THE PUBLISHED VERSION; this is the author’s final, peer-reviewed manuscript. The published version may be 
accessed by following the link in the citation at the bottom of the page. 
American Journal of Pathology, Vol 186, No. 6 (June 2016): pg. 1568-1581. DOI. This article is © Elsevier and permission 
has been granted for this version to appear in e-Publications@Marquette. Elsevier does not grant permission for this 




Evidence of Muscle Growth 
Vehicle-injected Acta1 H40Y mice were easily distinguishable 
from vehicle-injected WT mice, primarily on the basis of muscle size. 
The weights of individual major muscles (quadriceps, triceps, 
gastrocnemius) were significantly smaller in vehicle-injected Acta1 
H40Y mice compared with vehicle-injected WT mice (P < 0.0001) 
(Figure 2A). Muscle weight measurements at 16 WOL found that 
ActRIIB-mFc treatment produced significant increases in the weights of 
the quadriceps, triceps, and gastrocnemius muscles compared with 
vehicle-treated mice of the same genotype (P < 0.001). There was no 
gross evidence of selective hypertrophy or atrophy of specific muscles. 
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Figure 2. Skeletal muscle histopathologic findings in VEH- and ActRIIB-mFc–treated 
mice. A: Individual muscle weights from VEH- and ActRIIB-mFc–treated mice. Bars 
and asterisks denote significant (P < 0.05) differences between treatment groups 
with relevant comparisons. B: Representative areas of transversely sectioned 
quadriceps muscle after sectioning and staining with Gomori trichrome. Acta1 H40Y 
mice have pathologic aggregates of purple/red material that corresponds to 
aggregates of nemaline rod material. C: Frequency histogram illustrating myofiber size 
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distribution in the quadriceps muscles of VEH- and ActRIIB-treated mice. Asterisks 
reflect significant differences between treated and untreated animal groups, both in 
WT and Acta1 H40Y mice. ∗P < 0.05. Scale bar = 40 μm (B). ActRIIB, ActRIIB-mFc 
treated; VEH, vehicle; WT, wild type. 
Histologic evaluation of Acta1 H40Y mouse quadriceps muscle 
revealed numerous intracellular inclusions that were best visualized on 
Gomori trichrome stain, consistent with nemaline rods and with prior 
descriptions of muscle disease in this model (Figure 2B).18 Additional 
pathologic findings included excessive variation in fiber size and 
increased amounts of internally nucleated fibers. None of these 
pathologic findings were observed in WT quadriceps muscles. Mean 
± SD myofiber size of Acta1 H40Y mice (37.94 ± 0.58 μm) was only 
slightly smaller than that observed in WT mice (Table 2), although 
frequency histograms of fiber size revealed a difference in fiber size 
distributions due to disease (P < 0.05) (Figure 2C). With respect to the 
effects of ActRIIB-mFc treatment, treated WT animals had increases in 
mean overall fiber size (irrespective of fiber type), which also 
corresponded to significant increases seen in both the oxidative and 
glycolytic myofiber subpopulations (P < 0.05) (Table 2). The 
distribution of myofiber size in WT mice was shifted toward larger 
myofiber sizes as a result of ActRIIB-mFc treatment (Figure 2C and 
Table 2). Similarly, there was evidence of myofiber hypertrophy in 
Acta1 H40Y mice as a result of ActRIIB-mFc treatment, consistent with 
the observed increase in muscle weights. Quantitative evaluation of 
mean myofiber size revealed a significant increase in Acta1 H40Y 
oxidative fiber size with treatment, with nonsignificant trends toward 
increased mean fiber size in the glycolytic fiber population and in 
myofibers overall (Table 2). The myofiber size distributions of ActRIIB-
mFc–treated Acta1 H40Y mice were shifted toward larger myofiber 
sizes overall (P < 0.05) (Figure 2C). With respect to the presence of 
pathologic inclusions (nemaline rod aggregates), manual quantitation 
of fibers that contained aggregates of nemaline rods did not identify a 
treatment-associated decrease in these structures in the quadriceps 
muscle (Figure 2B and Table 2). The structure of these inclusions was 
investigated further by electron microscopy using glutaraldehyde-fixed 
tissue from the quadriceps muscle, which revealed the presence of 
nemaline rods and mitochondrial aggregates, sometimes in association 
with myofibrillar disarray (Supplemental Figure S1B). Myofibrillar 
inclusions were not observed in the absence of adjacent nemaline rod 
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disease, although nemaline rods were sometimes present without 
evidence of myofibrillar disarray or mitochondrial aggregation. 





 Mean myofiber size (MinFeret diameter, μm) 
 All fibers 42.70 ± 1.95 55.49 ± 2.04∗ 37.94 ± 0.58 44.46 ± 1.93 
 Oxidative fibers 30.08 ± 1.02 45.24 ± 1.29∗ 33.93 ± 0.80 41.63 ± 1.99† 
 Glycolytic fibers 46.28 ± 2.37 62.90 ± 2.60∗ 39.01 ± 0.68 45.76 ± 2.27 
 Pathologic 
inclusions (% of 
fibers) 
1.40 ± 0.50 0.90 ± 0.74 30.20 ± 2.86 35.50 ± 1.97 
Periurethral muscle 
 Myofiber size 
(MinFeret 
diameter, μm) 
52.25 ± 3.84 53.65 ± 3.90 50.26 ± 4.32 53.67 ± 4.77 
 Pathologic 
inclusions (% of 
fibers) 
0.00 ± 0.00 0.00 ± 0.00 55.91 ± 5.95 46.2 ± 8.66 
 Copulatory plugs 
(% of animals) 
(n/N) 
35 (5/14) 76 (10/13)∗ 82 (9/11)∗ 91 (10/11) 
 Inflammation (% 
of animals) (n/N) 
0 (0/14) 0 (0/13) 91 (10/11)† 18 (2/11) 
Values are expressed as means ± SEM unless otherwise indicated. 
VEH, vehicle; WT, wild type. 
∗P < 0.05 between WT/ActRIIB-mFc or Acta1 H40Y/VEH and WT/VEH. 
†P < 0.05 between Acta1 H40Y/ActRIIB-mFc and Acta1 H40Y/VEH. 
The diaphragm and gastrocnemius muscles were also 
qualitatively evaluated histologically (Supplemental Figure S1A), but 
these muscles were not evaluated using quantitative methods. 
ActRIIB-mFc treatment produced marked hypertrophy of the 
diaphragm muscles of both WT and Acta1 H40Y mice, particularly in 
glycolytic myofibers. Treatment-induced myofiber hypertrophy was 
also apparent in the gastrocnemius muscles of WT mice, but 
treatment-induced hypertrophy was less apparent in Acta1 H40Y 
gastrocnemius muscles (compared with the WT gastrocnemius and the 
Acta1 H40Y quadriceps and diaphragm muscles). Similar to what was 
observed in the quadriceps muscle, there did not appear to 
be a treatment-related change in pathologic inclusions in the 
diaphragm or gastrocnemius muscles. 
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Mortality of Acta1 H40Y Mice Is Associated with Bladder Outlet 
Obstruction 
The Acta1 H40Y mouse model has a curious pattern of mortality 
that is primarily restricted to a significant population of male mice at 5 
to 13 WOL. This mortality is not observed in Acta1 H40Y females, 
implying that there may be critical sex-related differences in 
mechanisms leading to mortality in this model. Indeed, further study 
of these mice revealed that myofilament function identified sex-related 
differences in the contractile performance of the tibialis anterior 
muscle, but there was no such dimorphism in the diaphragm, which is 
largely responsible for respiratory function.31 Necropsy findings 
performed in our study indicate that sex-related survival differences in 
Acta1 H40Y mice may primarily be caused by anatomical factors. 
Similar to prior studies,18 we have only observed significant mortality 
in the 5- to 13-week period in male mice in our Acta1 H40Y colony. 
Pathologic examination on necropsy revealed that mortality of Acta1 
H40Y mice in our treatment study was typically associated with 
marked bladder distension (Figure 3, A and B) and accompanied by 
variable degrees of hemorrhage and necrosis in the genital and urinary 
tracts. In most cases, areas of induration, hemorrhage, and/or 
necrosis were clearly identified in the area of the prostatic urethra. 
This phenotype accounted for 34 of 36 Acta1 H40Y mice that died of 
disease during this study (23/24 in the Acta1 H40Y/vehicle group and 
11/12 in the Acta1 H40Y/ActRIIB-mFc group). Behaviorally, these 
animals had difficulty passing urine and had palpable distension of the 
bladder, but their ambulation and behavioral test results were not 
significantly affected until they were near-terminal. Dilatation of the 
bladder and ureters and hydronephrosis were observed in some 
animals, consistent with effects secondary to bladder outlet 
obstruction. This bladder outlet obstruction was not observed in the 
female Acta1 H40Y mice that were being used for breeding in our 
colony. Histologically, mice with bladder outlet obstruction typically 
had extensive inflammation of the urethra and surrounding tissues, 
particularly in the area of the prostate. Urinalysis results revealed 
increased numbers of red and white blood cells and increased urine 
protein in most cases (data not shown). Necrosis of this tissue and of 
tissues further upstream in the genital and urinary tracts was seen to 
variable degrees, but necrosis and inflammation of these regions were 
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never seen in the absence of obstruction of the urethra. The nature of 
the obstruction and the assessment of muscle structure in the urethral 
striated muscles were not clearly evaluable because of the extensive 
inflammation and tissue damage seen in these animals. However, a 
systematic investigation of Acta1 H40Y mice that survived to the 16-
week study end point was performed, and the genitourinary tracts 
were thoroughly examined. Compared with vehicle-injected WT mice, 
ActRIIB-mFc–injected WT mice and all Acta1 H40Y mice had a greater 
percentage of copulatory plugs (a concretion formed by mice involved 
in reproductive behavior) (Figure 3, C and D) in the prostatic 
urethra.32,33 Copulatory plugs may be found as an incidental finding 
(due to agonal ejection of the plug) or as a legitimate cause of urinary 
tract obstruction, and the distinction often relies on the presence of 
inflammation as evidence of premortem obstruction. Inflammation of 
the genitourinary tract was quantified (in terms of its presence or 
absence in adequately sampled areas) as an indicator of significant 
premortem urinary tract obstruction, which revealed an absence of 
inflammation in WT mice, a very high number [11 (82%) of 13 
samples] of vehicle-injected Acta1 H40Y mice with inflammation and 
a significantly (P < 0.001) lower number of mice with inflammation in 
the ActRIIB-mFc–treated Acta1 H40Y group [2 (18%) of 11 samples] 
(Figure 3E). This finding suggests treatment-associated changes to 
urethral striated muscle may allow improved copulatory plug ejection 
and prevent complications of urinary tract obstruction. Evaluation of 
urethral striated muscle (likely involved in the ejection of copulatory 
plugs from the urethra) of male Acta1 H40Y mice revealed marked NM, 
including actin-positive inclusions in many fibers (Figure 3, F and G). 
These inclusions likely corresponded to a combination of nemaline rods 
and myofibrillar material, similar to what was seen on electron 
microscopy of the quadriceps muscle (Supplemental Figure S1). 
Quantitative analysis of the urethral striated muscles revealed that the 
mean myofiber size was similar when comparing all four treatment 
groups (Table 2), although ActRIIB-mFc treatment produced slight 
trends toward increased mean fiber size in both WT and Acta1 H40Y 
mice (Figure 3H). Myofiber atrophy (as indicated by small fibers with 
angulated cellular contours) was observed in some Acta1 H40Y mice in 
association with inflammation, but these samples were not included in 
the quantitative analysis because of the likely effect of the 
inflammation. Actin-positive cytoplasmic inclusions were only seen in 
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Acta1 H40Y (and not WT) mice, and there was a nonsignificant trend 
of decreased numbers of these inclusions in the urethral striated 
muscles of ActRIIB-mFc Acta1 H40Y mice (Acta1 H40Y/vehicle 
= 55.91% ± 5.95%, Acta1 H40Y/ActRIIB = 46.2% ± 8.66%) 
(Table 2). Although other organs (including the heart, lungs, brain, 
liver, spleen, small intestine, and colon) were evaluated histologically 
at necropsy, no pathologic abnormalities were noted in these organs, 
including the lungs of treated WT mice that died during the treatment 
period. 
 
Figure 3. Genitourinary (GU) tract histopathologic findings in VEH- and ActRIIB-mFc–
treated mice. A and B: Gross and histologic evidence of urethral obstruction leading to 
bladder distension, inflammation (asterisk) and necrosis in a subset of Acta1 H40Y 
mice that died spontaneously during the trial. C and D: Assessment of copulatory 
plugs. C: Axial section of the GU tract of an ActRIIB-mFc–treated Acta1 H40Y mouse 
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at 16 weeks of age. A copulatory plug is evident, as is a large amount of urethral 
striated muscle surrounding the prostate. There is no evidence of inflammation or 
tissue necrosis in this specimen. D: Quantification of mice exhibiting intraurethral 
copulatory plugs out of (n) mice per group. E: Quantification of mice exhibiting GU 
tissue inflammation out of (n) mice per group. F and G: Immunostaining of urethral 
striated muscles for skeletal muscle actin reveals pathologic aggregates of actin 
(corresponding to nemaline rod aggregates) in numerous fibers in Acta1 H40Y mice 
(G), whereas these aggregates are absent in WT littermates (F). H: Frequency 
histogram illustrating myofiber size distribution in urethral striated muscles of VEH- 
and ActRIIB-mFc–treated mice. ∗P < 0.05, ∗∗∗P < 0.001. ActRIIB, ActRIIB-mFc treated; 
VEH, vehicle; WT, wild type. 
Hypertrophic Pathway Studies 
The activation of hypertrophic pathways in WT and Acta1 H40Y 
mice was investigated using Western blots. Phosphorylated and 
nonphosphorylated constituents of the Akt signaling pathway, 
including Akt, P70/S6k, rpS6, 4EBP1, and EEF2k, did not reveal 
significant differences with respect to genotype or treatment group 
(Figure 4). Levels of myostatin and the activin 2B receptor were both 
higher in vehicle-injected Acta1 H40Y mice compared with vehicle-
injected WT mice (P < 0.05). Treatment of WT mice with ActRIIB-mFc 
produced an increase in myostatin levels (P < 0.05), which is 
consistent with the effects of this agent in WT mice in our prior 
studies.15 In Acta1 H40Y mice, treatment with ActRIIB-mFc produced a 
decrease in myostatin levels (P < 0.05). With respect to ActRIIB 
levels, vehicle-injected Acta1 H40Y mice had variable but considerably 
higher levels of this protein than vehicle-injected WT animals 
(P < 0.02). Treatment with ActRIIB-mFc in both WT and Acta1 H40Y 
mice produced nonsignificant trends toward lower ActRIIB levels. 
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Figure 4. Expression of proteins related to myofiber growth in VEH- and ActRIIB-
mFc–treated mice. A: Western blots reveal protein expression of growth-associated 
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proteins in the quadriceps muscles of individual WT or Acta1 H40Y mice. B: Quantified 
protein expression (normalized to GAPDH expression) for each growth-associated 
protein shown in A. Protein extracted from the quadriceps muscle of four 16-week-old 
mice per treatment group were tested. ∗P < 0.05, ∗∗P < 0.01. ActRIIB, activin type IIB 
receptor; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; VEH, vehicle; 
WT, wild type. 
Discussion 
Myostatin Inhibition as a Therapeutic Strategy in NM 
Because of the possible association between myofiber size and 
weakness, we hypothesized that the pharmacologic induction of 
hypertrophy through myostatin/ActRIIB inhibition would produce 
symptomatic benefits in murine NM models. Therapeutic benefits 
related to myofiber size could be applicable to patients with NM and 
other disorders in which myofiber hypotrophy is a key pathologic 
feature, such as congenital fiber-type disproportion. In our prior work 
using ActRIIB-mFc as a myostatin inhibition strategy in two murine 
models of XLMTM, we observed myofiber hypertrophy that was 
functionally limited by abnormalities of ECC that are seen in that 
disease.14,15,34,35,36 Because multiple studies of NM models and human 
NM tissue have identified intact ECC in NM,16,17,18,19,20,21,22,23 we 
expected ActRIIB-mFc treatment to be more effective in murine 
models of NM. In the present study, we treated the Acta1 H40Y murine 
model of NM with ActRIIB-mFc to determine the potential of this 
symptomatic strategy in at least a subset of patients with NM. 
ActRIIB-mFc–treated heterozygous male Acta1 H40Y mice experienced 
benefits to total-body mass, muscle mass, myofiber size, and survival, 
consistent with positive treatment-induced behavioral and pathologic 
effects. Surprisingly, we determined that mortality in male Acta1 H40Y 
mice is associated with complications of urethral obstruction. Further 
study found significant NM pathologic findings in the striated muscles 
surrounding the prostate and urethra, and we believe that this 
represents a phenotype that is related to muscle weakness. 
The genetic heterogeneity of NM poses challenges for the 
development of treatments because any gene-specific treatment will 
likely only be suitable for a subpopulation of patients with NM. With 
respect to nonspecific therapies (such as hypertrophic therapies), it is 
currently difficult to predict treatment responsiveness across the NM 
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patient population because the degree to which different genetic 
causes produce distinct disease states remains unclear. Transgenic 
knock-in or knockout mouse models exist for mutations found in the 
NEB,20 ACTA1,18,19 TPM3,17 TNNT1,37 CFL2,38 KBTBD13, and KLHL407 
genes, and recent studies have explored treatment options in some of 
these models. For instance, the pathologic phenotype and clinical 
course of Acta1 H40Y mice were improved by crossing them with 
transgenic mice that produced myofiber hypertrophy through the 
overexpression of insulin-like growth factor-1 or FHL1 (but not c-ski),18 
suggesting that induction of myofiber hypertrophy through at least 
some mechanisms would be beneficial in these mice. In addition, 
although the Tpm3 M9R NM model required a period of disuse to 
promote weakness, exercise (and presumably the hypertrophy it 
caused) was found to be beneficial in the recovery of this weakness.39 
These data suggest that hypertrophic agents (such as myostatin 
inhibitors) could provide substantial improvement of pathologic 
findings and symptoms in NM. These findings are also supported by 
reports of exercise as an effective strategy for minimizing disability in 
NM.40 In the current study, ActRIIB-mFc produced muscle hypertrophy 
but did not show the clear treatment-associated benefits to forelimb 
grip strength or ex vivo contractile function that were observed in 
treated WT littermates. The main evidence of therapeutic benefit was 
related to improvements in survival. Although this benefit is promising, 
further evaluation of myostatin inhibition in NM (in the context of other 
Acta1 models and models of other genetic causes of NM) is necessary 
to more definitively establish the potential of this therapeutic strategy. 
Pathologic Findings Associated with Mortality in this Study 
Prior work using the Acta1 H40Y model of NM described 
mortality of approximately half of hemizygote males at 1 to 3 months 
of age,18 which was presumably related to their skeletal muscle 
disease. A similar degree and timing of mortality were observed in the 
present study, but we additionally had the opportunity to look for 
unexpected causes of death in these mice because we evaluated them 
for potential systemic adverse effects. Surprisingly, most mice that 
died at 1 to 3 months of age had marked distension of the bladder 
with evident acute inflammation and necrosis in the genital and urinary 
tracts. This finding was consistent with the complications of 
obstruction in the distal urethra with secondary damage that involved 
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more proximal regions of the genital and urinary tracts. Histologically, 
this was sometimes observed in association with a concretion of 
seminal secretions (the so-called copulatory plug) that is a normal 
finding in mice but is not a feature of human reproductive function.33 
Although this copulatory plug is often observed within the urethra as 
an agonal finding and may produce bladder distension artifactually, the 
relevance of this finding in the current context is indicated by the 
presence of marked genitourinary inflammation in many Acta1 H40Y 
mice and the observation of apparent bladder distension and inability 
to pass urine in the terminal phase of disease in many Acta1 H40Y 
mice in our study. This phenomenon may explain the timing of 
mortality at 1 to 3 months (because this corresponds to a period when 
male mice reach sexual maturity and would begin producing these 
structures) and why female Acta1 H40Y mice do not experience 
mortality during this period.18 Pathologic evaluation of the 
genitourinary tract revealed that the urethral striated muscle had 
significant NM-associated pathologic findings in Acta1 H40Y mice, 
including intracellular aggregates that are strongly positive for skeletal 
muscle actin. Urethral striated muscle is similar but developmentally 
distinct from skeletal muscle,41 and the involvement of this type of 
striated muscle (similar to the striated muscle of the esophagus and 
perianal region) has not been studied in NM. Although this striated 
muscle is structurally and functionally similar to skeletal muscle, it is 
developmentally derived from splanchnic mesoderm (instead of being 
derived from somites as limb skeletal muscles are).42,43 Our findings 
suggest that urethral striated muscle weakness seen in Acta1 H40Y 
mice may affect reproductive function in male mice to the extent that 
copulatory plugs cannot be passed from the membranous urethra. 
Acta1 H40Y mice that were treated with ActRIIB-mFc had similar 
numbers of copulatory plugs, but the number of mice with 
genitourinary inflammation was markedly decreased. There were 
nonsignificant trends toward improved muscle condition in ActRIIB-
mFc–treated urethral striated muscle (including trends toward larger 
fiber size and decreased numbers of fibers with pathologic inclusions). 
It is possible that treatment-associated changes in urethral striated 
muscle strength and power improved the ability to pass copulatory 
plugs through the urethra, thereby improving the survival of ActRIIB-
mFc–treated Acta1 H40Y mice. The degree to which this phenotype is 
observed in other murine models of neuromuscular disease is unclear, 
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but it may be useful to include studies of genitourinary anatomy in 
characterization or treatment studies of neuromuscular disease. 
A recent study of Acta1 H40Y mice has identified distinct causes 
of weakness in different muscle types (limb muscles versus 
diaphragm),44 and it is possible that a similar difference exists between 
limb muscles and urethral striated muscles. Weakness in limb muscles 
was primarily due to abnormalities in actin-myosin interactions that 
affected cross-bridge cycling, whereas weakness in the diaphragm was 
more related to the presence of noncontractile areas in the myofibers. 
We found that ActRIIB-mFc induced hypertrophy in Acta1 H40Y mice 
in the limb muscles but were unable to find improvements in limb 
muscle strength. In vitro studies of muscle contraction, however, 
found the treatment to maintain the velocity and power of the soleus 
and EDL muscles. However, pathologic findings indicative of urinary 
tract obstruction (inflammation of the genitourinary tract and gross 
evidence of obstruction) improved as a result of ActRIIB-mFc therapy. 
There were trends toward decreased numbers of urethral striated 
muscle fibers that contain pathologic aggregates of actin in ActRIIB-
mFc–treated Acta1 H40Y mice (Table 2). Further study is required to 
determine the cause of weakness in Acta1 H40Y urethral striated 
muscles, but we posit that ActRIIB-mFc improves function of urethral 
striated muscle in a manner that is distinct from the major 
mechanisms responsible for weakness in limb muscles. Alternatively, it 
is possible that both limb skeletal muscles and urethral striated 
muscles have similar causes of weakness, but that the power required 
to eject copulatory plugs is considerably less than that required to 
produce measurable increases in isometric contraction strength. 
With respect to the ActRIIB-mFc–treated WT mice who died late 
in the trial period, the presence of large amounts of transudative 
thoracic fluid suggests the accumulation of fluid as the result of 
injections. Because this study implemented a uniform concentration of 
drug across all groups and then based treatment volume on animal 
weight, the animals that were the heaviest were recurrently given the 
largest treatment volumes. The accumulation of fluid further 
contributed to animal weight and compounded the problem, resulting 
in marked fluid overload in some of our heaviest animals (all of which 
were in the WT/ActRIIB-mFc group). This thoracic fluid overload was 
not observed in the other treatment groups. To avoid this complication 
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in future trials using ActRIIB-mFc, a higher concentration of the agent 
will be used to minimize the volume injected and improve clearance of 
fluid. 
Hypertrophic Signaling in Acta1 H40Y Mice 
Western blots were used in this study to determine the effect of 
the Acta1 H40Y mutation on hypertrophic signaling, and the degree 
that ActRIIB-mFc therapy changed signaling in these pathways. We 
have used this strategy previously to detect disease- and muscle-
specific signaling abnormalities that were associated with muscle-
specific treatment effects with ActRIIB-mFc in murine models of X-
linked myotubular myopathy.15 In this study, there was no evidence of 
muscle-selective treatment efficacy (with respect to fiber type or 
muscle tested) in Acta1 H40Y mice. There were no significant 
differences in hypertrophic pathway signaling when comparing vehicle-
injected WT and Acta1 H40Y mice, and treatment with ActRIIB-mFc 
did not significantly affect the levels of these proteins. There were, 
however, significant differences between WT and Acta1 H40Y mice 
with respect to the levels of myostatin and the ActRIIB, with vehicle-
injected Acta1 H40Y mice having significantly higher levels of both 
proteins compared with vehicle-injected WT mice. This higher level of 
myostatin in affected mice may provide an explanation for the trend 
toward smaller myofibers in Acta1 H40Y mice (and the prior reports of 
myofiber smallness in these mice18). However, the degree to which 
higher myostatin or ActRIIB levels affect therapeutic effectiveness is 
unclear because, as a soluble receptor decoy, ActRIIB-mFc should 
prevent the binding of myostatin to the ActRIIB and induction of its 
signaling cascade. Overall, though, the key finding here is that there 
are no disease-associated abnormalities of hypertrophic signaling in 
Acta1 H40Y mice, and thus no expectation that strategies to induce 
hypertrophy would be impaired in this model. 
Overall, these studies illustrate the first attempt at 
antimyostatin treatment in a mouse model of NM, which resulted in a 
variety of pathologic improvements and a moderate improvement in 
survival for male animals with urethral obstruction. Although muscle 
hypertrophy in response to treatment was apparent, there was little to 
no evidence of increased strength in limb muscles using a variety of 
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assays. Treatment-related improvements in survival were associated 
with changes in the degree of genitourinary obstruction and 
inflammation in Acta1 H40Y mice, which identified this phenomenon as 
a highly relevant phenotype in the assessment of this model. Because 
the circumstances of urinary obstruction are presumably due to 
weakness and pathologic findings in urethral striated muscles and this 
situation is unlikely to be unique to Acta1 H40Y mice, our study also 
identifies an important phenotype that should be considered across the 
spectrum of murine neuromuscular disease models. 
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Supplemental Figure S1. Additional pathologic studies of skeletal muscle in wild-
type (WT) and Acta1 H40Y mice. A: Gomori trichrome staining of the diaphragm and 
gastrocnemius muscles reveal the degree of myofiber hypertrophy and pathologic 
inclusion burden seen after vehicle (VEH) or ActRIIB-mFc (ActRIIB) treatment of WT 
or Acta1 H40Y mice. B: Electron microscopy (EM) reveals several pathologic 
abnormalities in Acta1 H40Y quadriceps muscle, including nemaline rods, and 
aggregates of mitochondria (yellow arrows), sometimes surrounded by myofibrillar 
disarray. Other areas (right) have nemaline rods/bodies without evidence of 
mitochondrial abnormalities or large-scale myofibrillar disorganization. Scale bars: 40 
μm (A); 2 μm (B). 
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